Toine C Egberts
Overview
Explore the profile of Toine C Egberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alsamil A, Gardarsdottir H, Leufkens H, Egberts T, Giezen T
Drug Discov Today
. 2023 Jul;
28(10):103725.
PMID: 37487844
The quality of biopharmaceuticals is carefully monitored by manufacturers and regulators to ensure safety and efficacy throughout the entire product life cycle. Quality defects can lead to post-approval regulatory actions...
2.
Alsamil A, Giezen T, Egberts T, Doevendans E, Leufkens H, Gardarsdottir H
Eur J Pharm Sci
. 2022 May;
175:106227.
PMID: 35636657
The manufacturing of biopharmaceuticals is complex, and minor changes in the process may affect quality attributes (QAs) that may, in turn, impact clinical outcomes. Regulatory documents from the European Medicines...
3.
Alsamil A, Giezen T, Egberts T, Leufkens H, Gardarsdottir H
Pharmaceuticals (Basel)
. 2021 Mar;
14(3).
PMID: 33669108
Regulatory approval of biosimilars predominantly relies on biosimilarity assessments of quality attributes (QAs), particularly the potentially critical QAs (pCQAs) that may affect the clinical profile. However, a limited understanding exists...
4.
Alsamil A, Giezen T, Egberts T, Leufkens H, Gardarsdottir H
Biologicals
. 2021 Jan;
69:30-37.
PMID: 33454195
Biosimilar approval relies on the comparability of quality attributes (QAs), for which information can be derived from regulatory or scientific communities. Limited information is known about whether these sources are...
5.
Alsamil A, Giezen T, Egberts T, Leufkens H, Vulto A, van der Plas M, et al.
Eur J Pharm Sci
. 2020 Aug;
154:105501.
PMID: 32739253
Last years, more than 46 unique biosimilars were approved by EMA and/or US-FDA following patent expiration of reference products. Biosimilars are not identical like generics, but highly similar versions where...
6.
Timmerman A, Oliveira-Martens S, Snijder R, Nieman A, Egberts T
Biomed Tech (Berl)
. 2015 Sep;
60(4):381-7.
PMID: 26352353
Infusion therapy is widely used in hospitals. It is well known that medication errors constitute one of the highest risks to patient safety, leading to numerous adverse events concerning incorrect...
7.
Snijder R, Konings M, Lucas P, Egberts T, Timmerman A
Biomed Tech (Berl)
. 2015 Sep;
60(4):277-300.
PMID: 26352348
Infusion therapy is medically and technically challenging and frequently associated with medical errors. When administering pharmaceuticals by means of infusion, dosing errors can occur due to flow rate variability. These...
8.
Einarson A, Egberts T, Heerdink E
J Eval Clin Pract
. 2015 Mar;
21(4):579-83.
PMID: 25809719
Rationale: Knowledge transfer and translation (KT) has become an important component in health care systems worldwide. Antidepressant use in pregnancy has become a controversial subject for a number of reasons,...
9.
Willemen M, Mantel-Teeuwisse A, Straus S, Meyboom R, Egberts T, Leufkens H
Diabetes Care
. 2011 Jan;
34(2):369-74.
PMID: 21270195
Objective: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antidiabetic drugs. They inactivate incretin hormones but also have many other effects throughout the body, among which are effects on...
10.
Gregoor J, van der Weide J, Loovers H, van Megen H, Egberts T, Heerdink E
Psychiatr Genet
. 2010 Jun;
20(6):311-6.
PMID: 20562674
Background: Treatment with atypical antipsychotic agents is often complicated by dyslipidemia, which is a risk factor for cardiovascular disease. Objectives: To determine whether the LEPR Q223R, the LEP -2548G/A, and...